


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claims 1 to 62. (Canceled).

Claim 63. (Currently Amended) A compound or a pharmaceutically acceptable salt of the compound, wherein the compound has the structure:



wherein:


(i) R¹ is a group:



wherein X_d is H; and, X_e is Cl, I or Br;

or:


(ii) R¹ is a group:



wherein X_d and X_e are independently the same or different and are selected from Cl, Br, and I;

and wherein each R^6 is independently the same or different from the other and is selected from the group consisting of -H, and -OH;

R^7 is -H, a monophosphate or the structure:




;

with the proviso that when R^7 is H, then X_d is not H and X_e is not Br; and

~~wherein the compound may be in any enantiomeric, diastereomeric, or stereoisomeric form, including D form, L form, α anomeric form, and β anomeric form.~~

Claim 64. (Previously Presented) A compound according to claim 63, wherein:

R^1 is a group:




wherein X_d is H; and, X_e is Cl or Br.

Claims 65 to 67. (Canceled).

Claim 68. (Previously Presented) A compound according to claim 63, wherein:

R¹ is a group:




wherein X_d and X_e is Cl, I or Br.

Claim 69. (Previously Presented) A compound according to claim 68, wherein X_d and X_e is Cl or Br.

Claim 70. (Previously Presented) A compound according to claim 68, wherein X_d and X_e are each Br.


Claims 71 – 78. (Canceled).

Claim 79. (Previously Presented) A compound according to claim 63, having the structure:



wherein X_d is H; and, X_e is Cl or I.

Claim 80. (Previously Presented) A compound according to claim 63, having the structure:




wherein X_d is H; and, X_e is Cl, I or Br.

Claim 81. (Canceled).

Claim 82. (Canceled).

Claim 83. (Previously Presented) A compound according to claim 63, having the structure:



wherein X_d and X_e are independently the same or different and are selected from Cl, Br, and I.

Claim 84. (Canceled)

Claim 85. (Previously Presented) A composition comprising a compound according to any one of claims 63, 64, 68-70, 79, 80 and 83 and a carrier.

Claim 86. (Previously Presented) A pharmaceutical composition comprising a compound according to any one of 63, 64, 68-70, 79, 80 and 83, and a pharmaceutically acceptable carrier.

Claim 87. (Previously Presented) A method for screening for a therapeutic agent, comprising:

(a) contacting a sample containing a target cell with a compound according to any one of claims 63, 64, 68-70, 79, 80 and 83;

(b) contacting a separate sample of the target cell with a potential therapeutic agent; and

(c) comparing the samples for inhibition of cellular proliferation or cell killing.

Claim 88. (Previously Presented) A method according to claim 87, wherein the target cell is characterized as resistant to a chemotherapeutic drug.

Claim 89. (Previously Presented) A method according to claim 87, wherein the target cell is characterized as expressing a target enzyme that is amplified as a result of selection *in vivo* by chemotherapy.

Claim 90. (Previously Presented) A method according to claim 87, wherein the target enzyme is an endogenous intracellular enzyme that is overexpressed in the target cell.

Claim 91. to 93. (Canceled).

Claim 94. (Currently Amended) A method for inhibiting the growth of a cancer cell selected from the group consisting of a colon cancer cell, a breast cancer cell, and a fibrosarcoma cell ~~gastric cancer cell, a head and neck cancer cell, a liver cancer cell, an ovarian cancer cell or a pancreatic cancer cell~~ and wherein said cell overexpresses thymidylate synthase, comprising contacting the cell with an effective amount of the compound of any of claims 63, 64, 68-70, 79, 80 and 83.

Claim 95. (Currently Amended) The method of claim 94, wherein the cancer cell is a breast cancer cell, ~~an ovarian cancer cell~~ or a colon cancer cell.

Claim 96. (Currently Amended) A method for treating a cancer in a subject, wherein the cancer is selected from the group consisting of colon cancer, breast cancer ~~[[.]] and fibrosarcoma gastric cancer, head and neck cancer, liver cancer, ovarian cancer and pancreatic cancer,~~ comprising administering an effective amount of a compound of any of claims 63, 64, 68-70, 79, 80 and 83 to the subject.

Claim 97. (Currently Amended) The method of claim 96, wherein the cancer is breast cancer~~[[.]] or colon cancer or ovarian cancer.~~

Claim 98. (Previously Presented) The method of claim 96, wherein the subject is a human patient.

Claim 99. (Previously Presented) The method of claim 97, wherein the subject is a human patient.